Quarterly ResultAug 6, 2026, 04:32 PM
Cognition Therapeutics Q2 Net Loss $(3.9)M; Patent Extends Zervimesine to 2045
AI Summary
Cognition Therapeutics reported a reduced net loss of $(3.9) million for the second quarter of 2026, an improvement from $(6.7) million in the prior year. The company also announced significant progress in its clinical and corporate priorities, including a patent allowance for zervimesine that extends intellectual property protection through 2045. Discussions with the FDA for a planned Phase 3 trial in DLB psychosis are ongoing, with an aim to initiate the study in mid-2027.
Key Highlights
- Q2 2026 net loss was $(3.9) million, an improvement from $(6.7) million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.04), compared to $(0.11) in Q2 2025.
- Research and development expenses decreased to $5.1 million in Q2 2026 from $11.5 million in Q2 2025.
- Cash, cash equivalents, and restricted cash totaled $34.8 million as of June 30, 2026.
- Company estimates sufficient cash to fund operations into the fourth quarter of 2027.
- Received a patent allowance for zervimesine, extending intellectual property protection through 2045.
- Conducted a planned meeting with the FDA to discuss the design of a registrational study in DLB psychosis.
- Extended the ongoing expanded access program for zervimesine in DLB through 2027 with new funding.
Price Impact
More from CGTX